Genital Herpes: Competitive Landscape

• In 2024, more than 52 million diagnosed prevalent cases of HSV-2 infection are anticipated in the 16 countries covered in the analyst’s epidemiology forecast for GH.
• Nucleoside analogue antiviral drugs have been the mainstay of GH treatment for over two decades.
• The GH pipeline has a limited number of products in mid-to late-stage development, with only one product in Phase III and four products in Phase II.
• In the last 10 years, the US has been the top country for trial sites, as it hosted nearly 50% of the sites for GH clinical trials conducted globally.
• Acquisitions were the most prevalent deal type in North America, Europe, and Asia-Pacific.

Scope

Components of the report include :

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the genital herpes market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global genital herpes market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.